CoChat

Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC)

Wolter, P., Stefan, C., Decallonne, B., Dumez, H., Fieuws, S., Wildiers, H., Clement, P., Debaere, D., Van Oosterom, A., Schöffski, P. · 2008 · Journal of Clinical Oncology
Cited by 47

The DOI matches its Crossref record.

Abstract

5126 Background: Sunitinib is a multi-target tyrosine kinase inhibitor with anti-angiogenic and anti-proliferative activity mediated by signal blockade of VEGFR1/2, KIT, PDGFR α/β, and FLT-3. Sunitinib has recently been approved for the treatment of RCC. Several studies have identified biochemical thyroid function test (TFT) abnormalities in approximately 2/3 of pts under sunitinib treatment. The possible association of the incidence of sunitinib-induced thyroid dysfunction and progression-free (PFS) and overall survival (OS) has not been analyzed yet. Methods: Thyroid function was evaluated prospectively in pts with advanced RCC on days l and 28 of each treatment cycle. Sunitinib was given at a daily oral dose of 50 mg 4 weeks on, 2 weeks off. For the statistical analysis the Kaplan-Meier method was used to construct curves for PFS and OS. The log-rank test was used to compare between pts with and without biochemical thyroid abnormalities. The analysis has been performed with SAS (version 9.1). The alpha-level has been set at 5%. No corrections have been made for multiple testing. Results: From 11/2005 to 12/2007 53 pts received sunitinib and 40 of them [m: 30, f: 10, median age 59 (42–81) years] were evaluable for thyroid function. In total, 28/40 pts (70%) developed TFT abnormalities: 13 pts (32.5%) developed clinical hypothyroidism requiring hormone substitution. Only in 12 pts (30%) no TFT abnormalities were observed. The median PFS was 3.6 mo (95%CI: 2.3 - 6.0) when there was no biochemical thyroid abnormality and 10.3 months (95%CI: 5.0 - 18.4 mo) in presence of biochemical TFT abnormalities (log rank p = 0,047). The median OS was 6.6 mo (95%CI: 3.3 - 7.9) when there was no biochemical thyroid abnormality and 18.2 mo (95%CI: 7.5 - 22.3) in presence of biochemical abnormalities (log rank p = 0,13). Conclusions: In pts with advanced RCC we observed a positive correlation between sunitinib-induced thyroid dysfunction and clinical outcome that requires further prospective evaluation. Understanding the biology and etiology of sunitinib-induced thyroid dysfunction and assessing its correlation with treatment outcome will help to define the role of thyroid dysfunction as a surrogate marker for efficacy of sunitinib in pts with advanced RCC. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Pfizer Oncology

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2008.26.15_suppl.5126

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 47

Metadata

Authors
Wolter, P., Stefan, C., Decallonne, B., Dumez, H., Fieuws, S., Wildiers, H., Clement, P., Debaere, D., Van Oosterom, A., & Schöffski, P.
Venue
Journal of Clinical Oncology
Published
2008-05-20
Volume
26
Issue
15_suppl
Pages
5126-5126
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2511396539
Cited by
47
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC). https://app.cochat.ai/papers/10.1200/jco.2008.26.15_suppl.5126
The paper
Wolter, P., Stefan, C., Decallonne, B., Dumez, H., Fieuws, S., Wildiers, H., Clement, P., Debaere, D., Van Oosterom, A., & Schöffski, P. (2008). Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.26.15_suppl.5126

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.